CMS Increases Oversight to Prevent Improper Medicaid Spending on Noncitizens
CMS ramps up oversight to stop misuse of Medicaid funds for noncitizen coverage, enforcing federal eligibility rules and recouping improper spending.
CMS ramps up oversight to stop misuse of Medicaid funds for noncitizen coverage, enforcing federal eligibility rules and recouping improper spending.
U.S. federal agencies issue new guidance and requests for information to improve transparency in prescription drug and hospital prices, aiming to enhance data accuracy and compliance.
CMS plans major expansion of Medicare Advantage RADV audits and proposes rules to limit Medicaid provider taxation practices, impacting insurer compliance and Medicaid financing.
CMS expands Medicare Advantage audits from 2018-2024, intensifying compliance demands and financial scrutiny for major health insurers like UnitedHealth, CVS, and Humana.
CMS excludes obesity drugs from 2026 Medicare coverage, citing cost concerns; Eli Lilly criticizes the decision impacting obesity management treatments.
Analysis of inflation rebate implementation under the Inflation Reduction Act highlights the need to include Medicare Advantage enrollees to maximize drug cost savings and deter pharmaceutical price hikes.
Record health insurance enrollment on the 2025 exchanges driven by ACA subsidies faces uncertainty amid proposed federal cuts. CMS reports enrollment up 13%.
CMS issued final rules and updates for Medicare Advantage and Part D programs for 2026, including Inflation Reduction Act implementations and inpatient care protections.
The Trump administration is advancing plans to make Medicare Advantage the default enrollment for all Medicare recipients, raising concerns about beneficiary choice and increased costs to taxpayers.
Explore how conservative proposals to alter Medicare enrollment could boost Medicare Advantage participation, impacting program costs and market dynamics.